🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Mulligan Mobilization With Movement Versus Conventional Physiotherapy on Ankle Range of Motion, Mobility, Pain, and Quality of Life in Patients With Type 2 Diabetes Mellitus

RecruitingNAAges 50 Years - 70 YearsAllIbadat International University, Islamabad
NCT07827625 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Type 2 Diabetes Mellitus (T2DM) is a major global health concern associated with chronic hyperglycemia, oxidative stress, and accumulation of advanced glycation end-products, which impair connective tissue function and commonly restrict ankle (tibiotalar) mobility. Reduced ankle range of motion, neuropathic pain, and gait instability significantly impair daily activities and quality of life in this population, and reduced ankle mobility is further associated with increased risk of diabetic foot ulceration. Conventional physiotherapy is widely used to address these impairments through exercise, stretching, and strengthening, but may not fully resolve mechanical joint restrictions. Mulligan's Mobilization with Movement (MWM) is a manual therapy technique in which a sustained glide is applied to the ankle during active weight-bearing movement, correcting positional faults and improving dors

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 50-70 years * Both male and female * Diabetes Mellitus \> 5 years' duration * Willing to participate and provide informed consent * Pain rated between 3-7 on the Numeric Pain Rating Scale (NPRS) * Ankle dorsiflexion range of motion ≤10° on goniometric assessment Exclusion Criteria: * History of recent lower-limb surgery, fracture, or dislocation (\<6 months) * Active diabetic foot ulcer or Charcot foot * Any inflammatory joint disease (e.g., rheumatoid arthritis) * Congenital foot deformity * Diagnosed diabetic peripheral neuropathy
💊

What it tests

  • Experimental
  • Control
📍

Where

1 site
Ibadat International University
Islamabad, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy